Inhibition of the Ê-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.

Prelowska, Monika K; Mehlich, Dawid; Ugurlu, M Talha; Kedzierska, Hanna; Cwiek, Aleksandra; Kosnik, Artur; Kaminska, Klaudia; Marusiak, Anna A; Nowis, Dominika

Inhibition of the Ê-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.

Prelowska, Monika K; Mehlich, Dawid; Ugurlu, M Talha; Kedzierska, Hanna; Cwiek, Aleksandra; Kosnik, Artur; Kaminska, Klaudia; Marusiak, Anna A; Nowis, Dominika.

Afiliação

Prelowska MK; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland. Electronic address: m.prelowska@cent.uw.edu.pl.
Mehlich D; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland; Doctoral School of Medical University of Warsaw, Warsaw, Poland; Laboratory of Centre for Preclinical Research, Department of Methodology, Medical University of Warsaw, Warsaw, Poland; Laboratory of Experi
Ugurlu MT; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Kedzierska H; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Cwiek A; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Kosnik A; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Kaminska K; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Marusiak AA; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland.
Nowis D; Laboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Poland; Laboratory of Experimental Medicine, Medical University of Warsaw, Poland. Electronic address: dominika.nowis@wum.edu.pl.

Cancer Lett ; 507: 13-25, 2021 06 01.

Article em En | MEDLINE | ID: mdl-33713737

Assuntos

Sistema ASC de Transporte de Aminoácidos/antagonistas & inibidores; Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Bortezomib/farmacologia; Glutamina/análogos & derivados; Glutamina/metabolismo; Mieloma Múltiplo/tratamento farmacológico; Oligopeptídeos/farmacologia; Complexo de Endopeptidases do Proteassoma/metabolismo; Inibidores de Proteassoma/farmacologia; Sistema ASC de Transporte de Aminoácidos/genética; Sistema ASC de Transporte de Aminoácidos/metabolismo; Apoptose/efeitos dos fármacos; Autofagia/efeitos dos fármacos; Linhagem Celular Tumoral; Resistencia a Medicamentos Antineoplásicos; Sinergismo Farmacológico; Estresse do Retículo Endoplasmático/efeitos dos fármacos; Glutamina/farmacologia; Humanos; Antígenos de Histocompatibilidade Menor/genética; Antígenos de Histocompatibilidade Menor/metabolismo; Mieloma Múltiplo/enzimologia; Mieloma Múltiplo/genética; Mieloma Múltiplo/patologia; Estresse Oxidativo/efeitos dos fármacos; Resposta a Proteínas não Dobradas/efeitos dos fármacos

Palavras-chave

Plasma cell myeloma; Proteasome inhibitors; Unfolded protein response; Ê-glutamine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Protocolos de Quimioterapia Combinada Antineoplásica / Sistema ASC de Transporte de Aminoácidos / Complexo de Endopeptidases do Proteassoma / Inibidores de Proteassoma / Bortezomib / Glutamina / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google